

**Lundquist Institute for Biomedical Innovation
at Harbor-UCLA Medical Center
Institutional Biosafety Committee
Meeting Minutes
07/22/2025
Virtual – Emergency Meeting**

MEMBERS PRESENT	MEMBERS ABSENT
David Applebaum, M.S. Fawzia Bardag-Gorce, Ph.D. Rami Doueiri, Ph.D. Adrienne Zweifel, Ph.D.	Helen Chun, Ph.D. Scott Filler, M.D. Fang Wang, Ph.D.
STAFF PRESENT	STAFF ABSENT
Elizabeth Burrola, CIP Rosa Harmon, CPIA Annie Hilo	Rosemary Madnick, MBA

CALL TO ORDER

The meeting was called to order by Fawzia Bardag-Gorce, Ph.D. at 3:01 PM.

BUA REVIEW

INITIAL REVIEWS

IBC #: IBC 2025-23073-01

PI: Ashraf Ibrahim, Ph.D.

iRIS Ref #: 062607

Summary: The purpose of these studies is to assess the activity of BAL2062 in combination with azoles in established immunosuppressed murine models of: Inhalational infection due to *Mucor circinelloides*, *Scedosporium apiospermum*, or *Lomentospora prolificans*. Hematogenously disseminated infections, including fusariosis due to *F. solani* and candidiasis due to *Candida auris*.

Inserts: NA

Vectors: NA

Pathogens: *Mucor circinelloides*, *f. jenssenii* DII5-131, *F. solani* 95–2478, *Scedosporium apiospermum*, *Lomentospora prolificans*

Risk Assessment: Risk Group 2

Containment: ABSL-2

Training: Training has been verified by the Research Compliance Office Staff and EHS.

NIH Guidelines: NA

Conflicts: NAMotion: A motion was made and seconded to REQUIRE MODIFICATIONS TO SECURE APPROVAL of the BUA.

Institutional Biosafety Committee
Meeting Minutes
07/22/2025

Modifications Required to BUA:

1. Section 4.0 - Background Information

The PI is to ensure all personnel listed are current in their Biosafety Training and update all of the personnel entries in item 4.4 to include the most recent Biosafety Training Date.

2. Section 5.0 - Description of Procedure(s)/Research

A. Experimental Procedures – The PI is to describe how the lab will receive the fungal agents from collaborators (e.g., freezer stock, stab culture, etc) and how the lab will begin to culture the agents from the sources.

B. Experimental Procedures - For spore collection, the lab is not permitted to use laminar flow hoods as they only provide product protection and do not provide adequate protection to personnel and environment. The PI is to clearly state spore collection will take place in a Class II, Type A2 biosafety cabinet.

C. Experimental Procedures - Will the fungi with culture volumes specified in Section 7.0 also be grown in the manner described? If not, the PI is to explain how these will be grown.

D. Experimental Procedures - Will the intratracheal inoculations be performed inside an engineering control, such as a BSC? If so, the PI is to explicitly state this.

E. Experimental Procedures - Will infected mice be imaged? If so, the PI is to clearly describe.

F. Experimental Procedures – The PI is to include Fusarium's IV route of inoculation.

G. Experimental Procedures – The PI is to include what the purified nucleic acids will be used for (e.g., sequencing, rtPCR, etc). If fungal burden of tissues will be assessed via plating of serial dilutions, the PI is to describe this as well.

H. Assessment of Hazardous Potential – The PI is to delete the sentence "None of the laboratory personnel fall into this high-risk category." as it is not appropriate information to be included here as the medical status of an individual in the lab can change.

I. Assessment of Hazardous Potential – The PI is to state whether the antifungal resistance profile for the agents used in this work are available and confirm that a copy of this profile is readily available for staff to reference.

J. Containment Conditions-(1) Rhizopus, (2) human cell culture, (3) E.coli, (4) the use of toxins/ricin and mucoricin are all mentioned here, but are absent elsewhere within this BUA. The PI is to address this discrepancy and update this section to only include agents and work listed in Section 7.0 of this BUA.

K. Emergency Procedures – The PI is to update this section to only include agents listed in Section 7.0 of this BUA.

L. Emergency Procedures – The PI is to remove the highlighted "BSO Comment" and revise the rest of the texts to show statements and not questions.

Institutional Biosafety Committee
Meeting Minutes
07/22/2025

M. Since this work does not involve human cells, the PI is to remove all references to human cells in this BUA.

3. Section 6.0 - Risk Assessment

A. The PI is to update the certification date of the biosafety cabinet

B. BSL1/BSL2 – The PI is to de-select BSL-1/ABSL-1 since all work describe will be under BSL-2. The PI is to explicitly state that all work will be under BSL-2.

C. PPE – The PI is to explicitly state what PPE will be used for which procedures (e.g., spore handling, intratracheal inoculations, intravenous inoculations, tissue homogenization, etc)

D. Equipment - 1. What equipment will be used with Fusarium? 2. The PI is to include the homogenizer probe, spectrophotometer, any freezers or refrigerators used to store the material. 3. The PI is to remove the E.coli equipment list if E.coli will not be included on this BUA and the hemocytometers if those are also not being used here.

E. NIH Guidelines - This work does not fall under the NIH Guidelines; The PI is to select the 'Not Applicable' option.

4. Section 8.0 - Infectious Agents/Toxins (Excluding Viral Vectors)

A. Mucor - For the question "What is the largest volume of agent to be cultured?" the PI is to replace N/A with the amount of liquid added when collecting it from the plate.

B. F. solani – The PI is to provide the full genus name.

C. Scedosporium apiospermum - 1. The PI is to confirm that this agent will not be stored in a freezer or refrigerator (will the lab be receiving new shipments for each experiment). 2. The PI is to clarify what types of materials will be autoclaved for inactivation.

D. Lomentospora prolificans - 1. The PI is to confirm that this agent will not be stored in a freezer or refrigerator (will the lab be receiving new shipments for each experiment). 2. The PI is to clarify what types of materials will be autoclaved for inactivation.

E. Staff notes the following biological agents were included in the IACUC application but is not currently listed in the BUA. The PI is to update this section to include the following agents - Aspergillus fumigatus, Aspergillus terreus, Aspergillus flavus, and Rhizopus deleamar.

F. The PI is to confirm that Aspergillus will not be cultured under conditions that could enhance its pathogenicity or make the agent more dangerous.

G. The PI is to revise the section to include the hazardous potential for all listed agents.

Vote: For - 4, Opposed - 0, Absent - 0, Abstained – 0, Recused – 0

Institutional Biosafety Committee
Meeting Minutes
07/22/2025

With no further business, the meeting adjourned at 3:33 PM

Respectfully submitted,

DocuSigned by:

Fawzia Gorce

Fawzia Bardag-Gorce, Ph.D.

Institutional Biosafety Committee

cc: Research Committee Agenda